Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Combe

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Annals of the Rheumatic Diseases|May 22, 2010
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))P Emery, A Deodhar, W F Rigby, et al.
Annals of the Rheumatic Diseases|January 7, 2006
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)B Combe, R Landewe, C Lukas, et al.
RMD Open|October 29, 2015
Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registryJ H Salmon, P Cacoub, B Combe, et al.
Arthritis Care & Research|August 27, 2010
Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registryB Terrier, D Launay, G Kaplanski, et al.
Annals of the Rheumatic Diseases|May 23, 2012
Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registryJ E Gottenberg, P Ravaud, A Cantagrel, et al.
Clinical and Experimental Rheumatology|June 8, 2002
Differences in understanding and application of 1987 ACR criteria for rheumatoid arthritis and 1991 ESSG criteria for spondylarthropathy. A pilot surveyJ M Berthelot, H J Bernelot-Moens, M Klarlund, et al.
Annals of the Rheumatic Diseases|November 20, 2004
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseasesJ-E Gottenberg, L Guillevin, O Lambotte, et al.
Medecine Et Maladies Infectieuses|June 30, 2015
French guidelines for the management of chikungunya (acute and persistent presentations). November 2014F Simon, E Javelle, A Cabie, et al.
Annals of the Rheumatic Diseases|June 7, 2015
Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registryJ H Salmon, J E Gottenberg, P Ravaud, et al.
Annals of the Rheumatic Diseases|September 16, 2008
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritisT Karonitsch, D Aletaha, M Boers, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Annals of the Rheumatic Diseases|May 22, 2010
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))P Emery, A Deodhar, W F Rigby, et al.
Annals of the Rheumatic Diseases|January 7, 2006
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)B Combe, R Landewe, C Lukas, et al.
RMD Open|October 29, 2015
Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registryJ H Salmon, P Cacoub, B Combe, et al.
Arthritis Care & Research|August 27, 2010
Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registryB Terrier, D Launay, G Kaplanski, et al.
Annals of the Rheumatic Diseases|May 23, 2012
Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registryJ E Gottenberg, P Ravaud, A Cantagrel, et al.
Clinical and Experimental Rheumatology|June 8, 2002
Differences in understanding and application of 1987 ACR criteria for rheumatoid arthritis and 1991 ESSG criteria for spondylarthropathy. A pilot surveyJ M Berthelot, H J Bernelot-Moens, M Klarlund, et al.
Annals of the Rheumatic Diseases|November 20, 2004
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseasesJ-E Gottenberg, L Guillevin, O Lambotte, et al.
Medecine Et Maladies Infectieuses|June 30, 2015
French guidelines for the management of chikungunya (acute and persistent presentations). November 2014F Simon, E Javelle, A Cabie, et al.
Annals of the Rheumatic Diseases|June 7, 2015
Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registryJ H Salmon, J E Gottenberg, P Ravaud, et al.
Annals of the Rheumatic Diseases|September 16, 2008
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritisT Karonitsch, D Aletaha, M Boers, et al.
Pageof 16